Elicera Therapeutics AB Logo

Elicera Therapeutics AB

Develops CAR T-cell & oncolytic virus therapies for cancer, enhanced by its iTANK platform.

ELIC | ST

Overview

Corporate Details

ISIN(s):
SE0015382080 (+1 more)
LEI:
549300I35L0R4INBFG27
Country:
Sweden
Address:
C/O Elicera Therapeutics AB, 402 24 Göteborg
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Elicera Therapeutics AB is a clinical-stage immuno-oncology company that develops cell and gene therapies for immune-based cancer treatments. The company's work focuses on two core technology areas: oncolytic viruses and Chimeric Antigen Receptor (CAR) T-cell therapies. Elicera's key asset is the proprietary iTANK (Immuno-Oncology Targeting and Killing) technology platform, a universal solution designed to enhance the efficacy of any CAR T-cell therapy by enabling a multi-targeted immune attack, particularly against solid tumors. The company's pipeline includes four drug candidates, with its oncolytic virus (ELC-100) and CAR T-cell therapy (ELC-301) in or entering clinical phase I/II trials for neuroendocrine tumors and B-cell lymphoma, respectively.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Elicera Therapeutics AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Elicera Therapeutics AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-03-11 Margareth Jorvid Other Other 21,700 40,145.00 SEK

Peer Companies

Company Country Ticker View
Pluri Inc. Logo
Develops placenta-based cell therapeutics using a proprietary 3D cell-expansion platform.
Israel PLUR
A global supplier of generic APIs using AI to accelerate drug development.
South Korea 041910
Poltreg S.A. Logo
Pioneering T-regulatory cell therapies for autoimmune diseases like diabetes, MS, and ALS.
Poland PTG
PolyPeptide Group AG Logo
A global CDMO specializing in peptide and oligonucleotide APIs for pharma and biotech partners.
Switzerland PPGN
Develops sensitive point-of-care biomarker diagnostics for human and animal health.
South Korea 335810
A global CDEMO offering end-to-end solutions for antibody therapeutics and biologics.
South Korea 334970
Develops affordable biosimilars and novel antibody drugs for life-threatening diseases.
Singapore 950210
Develops protein-based immunotherapies for metabolic diseases, immune disorders, and cancer.
South Korea 296160
PROTEINA CO.,LTD. Logo
A biotech firm specializing in proteomics for drug discovery and diagnostics in oncology.
South Korea 468530
PROTIA INC. Logo
Develops IVD kits and instruments for allergy, POCT, infectious & autoimmune diseases.
South Korea 303360

Talk to a Data Expert

Have a question? We'll get back to you promptly.